GenVec (NASDAQ: GNVC) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare GenVec to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.
This table compares GenVec and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for GenVec and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GenVec currently has a consensus target price of $7.00, suggesting a potential downside of 2.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.13%. Given GenVec’s competitors stronger consensus rating and higher probable upside, analysts clearly believe GenVec has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares GenVec and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|GenVec Competitors||$217.36 million||-$39.57 million||-59.83|
GenVec’s competitors have higher revenue, but lower earnings than GenVec. GenVec is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
6.2% of GenVec shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.1% of GenVec shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
GenVec competitors beat GenVec on 9 of the 11 factors compared.
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
What are top analysts saying about GenVec? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GenVec and related companies.